WallStreetZenWallStreetZen

NASDAQ: PHAT
Phathom Pharmaceuticals Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for PHAT

Based on 5 analysts offering 12 month price targets for Phathom Pharmaceuticals Inc

Min Forecast
$5.00-60.25%
Avg Forecast
$16.40+30.37%
Max Forecast
$28.00+122.58%

Should I buy or sell PHAT stock?

Based on 5 analysts offering ratings for Phathom Pharmaceuticals Inc.

Buy
Strong Buy
1 analysts 20%
Buy
3 analysts 60%
Hold
1 analysts 20%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although PHAT's forecast from analysts indicates a "Buy", our proven Zen Rating quant model rates PHAT as a "Sell". Stocks with a Zen Rating of Sell have had an average return of -4.50% per year. Learn More

Be the first to know when Wall Street analysts revise their PHAT stock forecasts and price targets.

PHAT stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-06-09
lockedlocked$00.00+00.00%2025-06-09
lockedlocked$00.00+00.00%2025-06-06
lockedlocked$00.00+00.00%2025-05-02
lockedlocked$00.00+00.00%2025-05-02

1 of 1

Forecast return on equity

Is PHAT forecast to generate an efficient return?

Company
-11.55%
Industry
122.74%
Market
-47.8%
PHAT's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is PHAT forecast to generate an efficient return on assets?

Company
13.29%
Industry
46.26%
PHAT is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

PHAT earnings per share forecast

What is PHAT's earnings per share in the next 2 years based on estimates from 2 analysts?

Avg 1 year Forecast
-$2.77
Avg 2 year Forecast
$0.24

PHAT revenue forecast

What is PHAT's revenue in the next 3 years based on estimates from 2 analysts?

Avg 1 year Forecast
$172.6M+110.8%
Avg 2 year Forecast
$359.8M+339.55%
Avg 3 year Forecast
$579.7M+608.13%
PHAT's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

PHAT revenue growth forecast

How is PHAT forecast to perform vs Biotechnology companies and vs the US market?

Company
91.48%
Industry
82.98%
Market
10.98%
PHAT's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
PHAT's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

PHAT vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
PHAT$12.58$16.40+30.37%Buy
IMNM$10.16$25.17+147.71%Strong Buy
IOVA$2.45$11.90+385.71%Strong Buy
CDTX$66.96$58.33-12.88%Strong Buy
QURE$15.79$40.75+158.07%Strong Buy
View Top Biotech Stocks

Phathom Pharmaceuticals Stock Forecast FAQ

Is Phathom Pharmaceuticals Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 5 Wall Street analysts covering (NASDAQ: PHAT) stock is to Buy PHAT stock.

Out of 5 analysts, 1 (20%) are recommending PHAT as a Strong Buy, 3 (60%) are recommending PHAT as a Buy, 1 (20%) are recommending PHAT as a Hold, 0 (0%) are recommending PHAT as a Sell, and 0 (0%) are recommending PHAT as a Strong Sell.

If you're new to stock investing, here's how to buy Phathom Pharmaceuticals stock.

What is PHAT's earnings growth forecast for 2025-2026?

(NASDAQ: PHAT) Phathom Pharmaceuticals's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 5.32%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 15.39%.

Phathom Pharmaceuticals's earnings in 2025 is -$345,790,000.On average, 2 Wall Street analysts forecast PHAT's earnings for 2025 to be -$193,036,045, with the lowest PHAT earnings forecast at -$197,573,962, and the highest PHAT earnings forecast at -$188,498,127.

In 2026, PHAT is forecast to generate $16,406,318 in earnings, with the lowest earnings forecast at -$4,188,847 and the highest earnings forecast at $37,001,484.

What is PHAT's revenue growth forecast for 2025-2027?

(NASDAQ: PHAT) Phathom Pharmaceuticals's forecast annual revenue growth rate of 91.48% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 82.98%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.98%.

Phathom Pharmaceuticals's revenue in 2025 is $81,859,000.On average, 2 Wall Street analysts forecast PHAT's revenue for 2025 to be $12,047,124,720, with the lowest PHAT revenue forecast at $11,983,593,870, and the highest PHAT revenue forecast at $12,110,655,570. On average, 3 Wall Street analysts forecast PHAT's revenue for 2026 to be $25,119,818,877, with the lowest PHAT revenue forecast at $24,488,001,082, and the highest PHAT revenue forecast at $25,775,373,473.

In 2027, PHAT is forecast to generate $40,469,151,520 in revenue, with the lowest revenue forecast at $37,941,182,199 and the highest revenue forecast at $42,349,245,799.

What is PHAT's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: PHAT) forecast ROA is 13.29%, which is lower than the forecast US Biotechnology industry average of 46.26%.

What is PHAT's Price Target?

According to 5 Wall Street analysts that have issued a 1 year PHAT price target, the average PHAT price target is $16.40, with the highest PHAT stock price forecast at $28.00 and the lowest PHAT stock price forecast at $5.00.

On average, Wall Street analysts predict that Phathom Pharmaceuticals's share price could reach $16.40 by Jun 9, 2026. The average Phathom Pharmaceuticals stock price prediction forecasts a potential upside of 30.37% from the current PHAT share price of $12.58.

What is PHAT's Earnings Per Share (EPS) forecast for 2025-2026?

(NASDAQ: PHAT) Phathom Pharmaceuticals's current Earnings Per Share (EPS) is -$5.19. On average, analysts forecast that PHAT's EPS will be -$2.77 for 2025, with the lowest EPS forecast at -$2.83, and the highest EPS forecast at -$2.70. In 2026, PHAT's EPS is forecast to hit $0.24 (min: -$0.06, max: $0.53).

What is PHAT's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: PHAT) forecast ROE is -11.55%, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.